鸦胆子油乳联合阿帕替尼+经肝化疗动脉栓塞术治疗肝癌对免疫功能、肝功能及血清指标的影响  

Effects of Yadanzi Injection(鸦胆子注射液)Combined with Apatinib and Transhepatic Chemoarterial Embolization in Treatment of Hepatocellular Carcinoma on Immune Function,Liver Function and Serum Indexes

作　　者：张文静[1] 王晓霞[1] 吉祥 李卓然 巩茳凯 侯洁[1] ZHANG Wenjing;WANG Xiaoxia;JI Xiang;LI Zhuoran;GONG Jiangkai;HOU Jie(Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital,Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University,Taiyuan 030013,Shanxi,China)

机构地区：[1]山西省肿瘤医院,中国医学科学院肿瘤医院山西医院,山西医科大学附属肿瘤医院,山西太原030013

出　　处：《中华中医药学刊》2024年第11期98-102,共5页Chinese Archives of Traditional Chinese Medicine

基　　金：国家重点研发计划项目(2016YFA0201500);白求恩公益基金项目(B-19-H-20200622);山西省中医药管理局科研课题计划项目(2023 ZYYB035)。

摘　　要：目的分析鸦胆子注射液联合阿帕替尼+经肝化疗动脉栓塞术(Transarterial chemoembolization,TACE)治疗肝癌对免疫功能、肝功能及血清指标的影响。方法纳入2022年2月—2023年2月收治的122例肝癌患者为研究对象,随机数字表法将其分为两组,对照组61例采用TACE联合阿帕替尼治疗,观察组61例在对照组的基础上联合鸦胆子注射液治疗,对比两组治疗效果、肝功能、肿瘤标志物水平、免疫功能及1年生存期等。结果观察组客观缓解率为37.70%(23/61),疾病控制率为95.08%(58/61),高于对照组的19.67%(12/61)、81.97%(50/61),组间比较差异有统计学意义(P<0.05);观察组肝功能指标丙氨酸氨基转移酶(Alanine aminotransferase,ALT)、天冬氨酸氨基转移酶(Aspartate aminotransferase,AST)、总胆红素(Total bilirubin,TBiL)水平低于对照组(P<0.05);治疗后观察组甲胎蛋白(Alpha-feto-protein,AFP)、癌胚抗原(Carcinoembryonic antigen,CEA)、血管内皮生长因子(Vascular endothelial growth factor,VEGF)、糖类抗原125(Carbohydrate antigen 125,CA125)水平均低于对照组(P<0.05);治疗后观察组CD_(4)^(+)T细胞(Cluster of differ-entiation 4 positive T cells,CD_(4)^(+))、CD_(4)^(+)/CD_(8)^(+)水平高于对照组,CD_(8)^(+)T细胞(Cluster of differentiation 8 positive T cells,CD_(8)^(+))低于对照组(P<0.05);观察组治疗后12个月生存率为85.25%,高于对照组的73.77%,组间比较差异显著(P<0.05)。两组肝癌患者一年总体累积生存曲线图结果显示差异显著(P<0.05)。结论鸦胆子注射液联合阿帕替尼+经肝化疗动脉栓塞术治疗肝癌能有效提高近期疗效,促进患者肝功能改善,降低血清肿瘤标志物水平,对提高患者免疫功能,延长生存期起到积极作用。Objective To analyze the effects of Yadanzi Injection(鸦胆子注射液)combined with apatinib and transhepatic chemotherapy arterial embolization(TACE)on immune function,liver function and serum indexes of hepatocellular carcinoma.Methods A total of 122 patients with liver cancer admitted to the hospital from February 2022 to February 2023 were included in the study.They were divided into two groups by random number table method.Sixty-one patients in the control group were treated with TACE and apatinib,and the other 61 patients in the observation group were treated with Yadanzi Injection on the basis of the control group.The therapeutic effect,liver function,tumor marker level,immune function and 1-year survival were compared between the two groups.Results The objective remission rate and disease control rate in the observation group were 37.70%and 95.08%,respectively,higher than 19.67%and 81.97%in the control group(P<0.05).The levels of liver function indexes(ALT,AST and TBiL)in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of AFP,CEA,VEGF and CA125 in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of CD+4 and CD_(4)^(+)/CD_(8)^(+)in the observation group were higher than those in the control group,and the level of CD_(8)^(+)was lower than that in the control group(P<0.05).The 12-month survival rate of the observation group was 85.25%,which was higher than that of the control group(73.77%),and the difference was significant(P<0.05).The cumulative oneyear overall survival curves for the two groups exhibited significant differences(P<0.05).Conclusion Yadanzi Injection combined with apatinib and TACE can effectively improve the shortterm curative effect,promote the improvement of liver function,reduce the levels of serum tumor markers,and plays a positive role in improving the immune function and prolonging the survival time of patients with liver cancer.

关 键 词：肝癌 鸦胆子注射液 阿帕替尼 经肝化疗动脉栓塞术 肝功能 免疫功能 中西医结合治疗 

分 类 号：R273.57[医药卫生—中西医结合]